This company in the US has a single drug doing $868m in annual revenue, throwing off $348m in operating cash flow, and sitting on $882m in cash. The market cap is $1.67bn. Generics don’t hit until 2030 and management has a plan. The market is pricing it like it goes to zero straight after. That gap is the entire setup.